Intratect (Human Normal Immunoglobulin)

Human Normal Immunoglobulin contains a broad spectrum of IgG antibodies harvested from healthy donors. These antibodies bind to a wide range of pathogens and toxins, neutralizing them, and they also interact with immune cells via Fc receptors to modulate inflammatory responses, thereby compensating for the patient’s deficient antibody production.

The dose of Intratect is individualized by the prescribing clinician. Factors such as the patient’s body weight, baseline serum IgG level, severity of the immunodeficiency, and clinical response guide the calculation. The prescriber will set the infusion volume, rate, and frequency according to established medical guidelines.

Safety data for Intratect in pregnancy and lactation are limited. The product’s pregnancy category is listed as unknown, so clinicians must weigh potential benefits against possible risks. Use is generally reserved for situations where the therapeutic advantage justifies exposure, and decisions should be made in consultation with a qualified healthcare professional.

To order Intratect, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams worldwide. After the request, the sales team will verify trade or institutional credentials, then provide pricing, availability, shipping details (including cold‑chain logistics if needed), and any required import documentation.

Intratect is comparable to other IVIG preparations in its core function of delivering pooled IgG antibodies. Differences may exist in manufacturing processes, stabilizers, concentration, and approved indications. Clinicians often consider factors such as infusion tolerability, product stability, and regional regulatory approvals when selecting an IVIG product for a specific patient population.

Intratect must be stored refrigerated at 2 °C to 8 °C. It should be kept in its original container, protected from light, and must never be frozen or shaken. Prior to administration, the solution may be gently mixed by inverting the vial; any product that appears discolored or contains particles should be discarded.

Intratect is administered intravenously by a qualified healthcare professional. The infusion is typically started at a low rate and gradually increased, based on the patient’s tolerance and the prescribing information. Vital signs are monitored throughout the infusion, and the total infusion time can range from one to several hours depending on the dose and clinical protocol.

Serious risks include anaphylactic or severe allergic reactions, thromboembolic events such as deep‑vein thrombosis or pulmonary embolism, acute renal failure, and aseptic meningitis. Patients should be observed closely for signs of these events during and after infusion, and any symptoms such as sudden shortness of breath, chest pain, or neurological changes require immediate medical attention.

Intratect is contraindicated in patients with a known severe IgA deficiency who have experienced anaphylaxis to blood products, as well as in individuals with a documented hypersensitivity to any component of the formulation. Caution is also advised for patients with uncontrolled hypercoagulable states, active renal disease, or those receiving high‑dose immunoglobulin therapy concurrently.